Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

A Study of Albuferon With Ribavirin in Interferon Treatment Experienced Subjects With Chronic Hepatitis C

ClinicalTrials.gov ID: NCT00097435

Public ClinicalTrials.gov record NCT00097435. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 8:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multi-Center, Randomized, Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of Albuferon (Recombinant Human Albumin-Interferon Alfa Fusion Protein) in Combination With Ribavirin in Interferon Treatment Experienced Subjects With Chronic Hepatitis C

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a Phase 2, multi-center, randomized, open-label study to evaluate the safety, tolerability, and efficacy of Albuferon in subjects with hepatitis C (HEP C) who failed to respond to previous interferon alfa therapy.

Study identification

NCT ID
NCT00097435
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Human Genome Sciences Inc.
Industry
Enrollment
115 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years to 65 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 2004 (Type not available)
Primary completion
Aug 2007 (Actual)
Completion
Aug 2007 (Actual)
Last update posted
Aug 2, 2013

2004 – 2007

United States locations

U.S. sites
8
U.S. states
6
U.S. cities
7
Facility City State ZIP Site status
Mayo Clinic Phoenix Arizona 85054 —
University of Florida CRC Gainesville Florida 32610 —
University of Florida at Jacksonville Jacksonville Florida 32209 —
Mayo Clinic Jacksonville Jacksonville Florida 32216 —
Johns Hopkins University Baltimore Maryland 21287 —
Mayo Clinic Rochester Rochester Minnesota 55905 —
Duke University Durham North Carolina 27710 —
Metropolitan Research Fairfax Virginia 22031 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00097435, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 2, 2013 · Synced Oct 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00097435 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →